



Docket No.:

March 14, 2005

Page 1 of 1

Please Direct All Correspondence to Customer Number **20995**

**AMENDMENT / RESPONSE TRANSMITTAL**

Applicant : Knoops, et al.  
App. No : 10/686,157  
Filed : October 15, 2003  
For : PEROXISOME-ASSOCIATED  
POLYPEPTIDE, NUCLEOTIDE  
SEQUENCE ENCODING SAID  
POLYPEPTIDE AND THEIR USES IN  
THE DIAGNOSIS AND/OR THE  
TREATMENT OF LUNG INJURIES  
AND DISEASES, AND OF  
OXIDATIVE STRESS-RELATED  
DISORDERS  
Examiner : Unknown  
Art Unit : 1646

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 14, 2005

(Date)

*Che S. Chereskin*

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Amendment in 4 pages.
- (X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

*Che S. Chereskin*

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404



LE30.001CP1

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant	:	Knoops, et al.
Appl. No.	:	10/686,157
Filed	:	October 15, 2003
For	:	PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR THE TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS
Examiner	:	unknown
Group Art Unit	:	1646

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Preliminary to examination on the merits, please amend the above-captioned U.S. application as follows.

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 4 of this paper.